PRX-3140 is under clinical development by Ology Bioservices and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PRX-3140’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRX-3140 overview

PRX-03140 (NTC-942) is under development for the treatment of Alzheimer's disease. It is administered orally. The drug candidate selectively targets 5-HT4 receptor.

It was under development post-traumatic stress disorder (PTSD), and mild cognitive impairment (MCI).

Ology Bioservices overview

Ology Bioservices is an US based integrated biopharmaceutical company. The company provides contract development and manufacturing services. The company manufactures biopharmaceutical products which include vaccines, antibodies, protein therapies and medical devices.

For a complete picture of PRX-3140’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.